Jove
Visualize
Contact Us

Related Concept Videos

Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

858
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
858
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

4.6K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.6K
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

1.2K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.2K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

208
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
208
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
  1. Home
  3. Efficacy And Safety Of Levosimendan In Severe Cardiac Dysfunction In Children Undergoing Cancer Chemotherapy And Hematopoietic Stem Cell Transplantation.
  1. Home
  3. Efficacy And Safety Of Levosimendan In Severe Cardiac Dysfunction In Children Undergoing Cancer Chemotherapy And Hematopoietic Stem Cell Transplantation.

Related Experiment Video

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
14:24

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model

Published on: January 21, 2018

12.1K

Efficacy and Safety of Levosimendan in Severe Cardiac Dysfunction in Children Undergoing Cancer Chemotherapy and

Rachit Mehta1, Indira Jayakumar1, Prasad Manne2

  • 1Department of Pediatric Onco-Critical Care, Apollo Hospitals, 320, Padma Complex, Anna Salai, Teynampet, Chennai, 600035 India.

Indian Journal of Hematology & Blood Transfusion : an Official Journal of Indian Society of Hematology and Blood Transfusion
|January 12, 2026

View abstract on PubMed

Summary
This summary is machine-generated.
Keywords:
CancerCardiac dysfunctionChildrenHSCTLevosimendan

More Related Videos

Cardiac Spheroids as in vitro Bioengineered Heart Tissues to Study Human Heart Pathophysiology
10:41

Cardiac Spheroids as in vitro Bioengineered Heart Tissues to Study Human Heart Pathophysiology

Published on: January 23, 2021

8.2K
Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes
08:47

Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes

Published on: December 16, 2022

2.8K

Related Experiment Videos

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
14:24

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model

Published on: January 21, 2018

12.1K
Cardiac Spheroids as in vitro Bioengineered Heart Tissues to Study Human Heart Pathophysiology
10:41

Cardiac Spheroids as in vitro Bioengineered Heart Tissues to Study Human Heart Pathophysiology

Published on: January 23, 2021

8.2K
Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes
08:47

Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes

Published on: December 16, 2022

2.8K

Levosimendan effectively treats heart dysfunction in pediatric cancer patients undergoing chemotherapy or stem cell transplants. This cardio-protective drug improved heart function and maintained normal blood pressure in young patients.

Area of Science:

  • Pediatric Cardiology
  • Oncology
  • Critical Care Medicine

Background:

  • Cancer therapy-related cardiac dysfunction is a critical, often under-recognized issue in pediatric hemato-oncology.
  • Levosimendan is explored for its cardio-protective potential in pediatric onco-critical care.

Purpose of the Study:

  • To assess the efficacy and safety of levosimendan in pediatric patients with cardiac dysfunction undergoing chemotherapy or HSCT.
  • To evaluate levosimendan's effectiveness as a first- and second-line cardiac support agent.

Main Methods:

  • Retrospective study of 62 children (up to 18 years) from January 2020 to December 2023.
  • Levosimendan administered as first-line for known dysfunction and second-line for shock with dysfunction.
  • Efficacy assessed via ejection fraction, Vasoactive-Inotropic Score (VIS), and echocardiography (ECHO).

Main Results:

  • 85% overall response rate observed in pediatric patients.
  • Mean ejection fraction improved from 50% to 58%.
  • Mean VIS reduction of 3.2; normal heart function on follow-up ECHO at four weeks.

Conclusions:

  • Levosimendan is a safe and effective treatment for acute heart failure in pediatric hemato-oncology patients with preserved blood pressure.
  • Results aid in tailoring critical care for pediatric hemato-oncology patients experiencing cardiac dysfunction.